紫草油联合表皮生长因子治疗索拉非尼所致手足综合征2例
Arnebiae Oil Combined with Epidermal Growth Factor for the Treatment of Sorafenib-Induced Hand-Foot Syndrome in 2 Cases
摘要: 索拉非尼作为一种小分子多靶点口服多激酶抑制剂，它作为单一用药的安全性和有效性已在实体肿瘤患者中进行的一系列研究中得到证实。但在临床症状的同时，其带来的皮肤不良反应给患者带来了极大的痛苦。临床发现2例使用索拉非尼治疗肝细胞癌后发生手足综合征的患者，应用紫草油联合表皮生长因子治疗后效果显著。现将病例情况整理如下，并讨论紫草油联合表皮生长因子治疗索拉非尼相关手足综合征的可能机制。
Abstract: The safety and efficacy of sorafenib, a small molecule multi-target oral multikinase inhibitor, as a single agent has been demonstrated in a series of studies conducted in patients with solid tumors. However, the clinical symptoms are accompanied by cutaneous adverse reactions that cause great distress to patients. Two patients who developed hand-foot syndrome after treatment with soraf-enib for hepatocellular carcinoma were clinically found to have significant results after applying comfrey oil combined with epidermal growth factor. The cases are compiled as follows, and the pos-sible mechanism of comfrey oil combined with epidermal growth factor for the treatment of soraf-enib-related hand-foot syndrome is discussed.
文章引用：苗长丰, 李雄, 房伟, 陈东东, 李惠民, 田宏伟. 紫草油联合表皮生长因子治疗索拉非尼所致手足综合征2例[J]. 临床医学进展, 2023, 13(3): 3336-3341. https://doi.org/10.12677/ACM.2023.133474

参考文献

[1] 刘宗超, 李哲轩, 张阳, 等. 2020全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1-14.
[2] Hartke, J., Johnson, M. and Ghabril, M. (2017) The Diagnosis and Treatment of Hepatocellular Carcinoma. Seminars in Diagnostic Pathology, 34, 153-159. [Google Scholar] [CrossRef] [PubMed]
[3] Llovet, J.M., Brú, C. and Bruix, J. (1999) Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification. Seminars in Liver Disease, 19, 329-338. [Google Scholar] [CrossRef] [PubMed]
[4] Tang, W., Chen, Z., Zhang, W., et al. (2020) The Mechanisms of Sorafenib Resistance in Hepatocellular Carcinoma: Theoretical Basis and Therapeutic Aspects. Signal Transduction and Targeted Therapy, 5, 87. [Google Scholar] [CrossRef] [PubMed]
[5] 李晓明, 姚立鹏, 程丽慧. 索拉菲尼对肝细胞癌凋亡和自噬相关蛋白表达的影响及耐药分析[J]. 中国现代普通外科进展, 2022, 25(1): 7-11.
[6] Damsin, T., Collignon, J., Lebas, E., et al. (2019) Treatment of Mucocutaneous Toxicity of Target Therapy in Oncology. Revue Médicale de Liège, 74, 7-14.
[7] Ehmann, L.M., Heinemann, V. and Wollenberg, A. (2011) New Tyrosine Kinase and EGFR Inhibitors in Cancer Therapy. Cardiac and Skin Toxicity as Relevant Side Effects. Part B: Skin. Internist (Berl), 52, 1359-1364. [Google Scholar] [CrossRef] [PubMed]
[8] Ai, L., Xu, Z., Yang, B., et al. (2019) Sorafenib-Associated Hand-Foot Skin Reaction: Practical Advice on Diagnosis, Mechanism, Prevention, and Management. Expert Review of Clinical Pharmacology, 12, 1121-1127. [Google Scholar] [CrossRef] [PubMed]
[9] Degen, A., Alter, M., Schenck, F., et al. (2010) The Hand-Foot-Syndrome Associated with Medical Tumor Therapy—Classification and Management. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 8, 652-661. [Google Scholar] [CrossRef] [PubMed]
[10] Lipworth, A.D., Robert, C. and Zhu, A.X. (2009) Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib. Oncology, 77, 257-271. [Google Scholar] [CrossRef] [PubMed]
[11] 赵德华, 王继生, 楚明明, 等. 抗肿瘤药物引起手足综合征的机制及防治措施[J]. 中国现代应用药学, 2019, 36(11): 1437-1442.
[12] 美国卫生及公共服务部, 国立卫生研究院, 国家癌症研究所. 常见不良反应事件评价标准4.0版[Z]. 2009.
[13] Miller, K.K., Gorcey, L. and McLellan, B.N. (2014) Chemotherapy-Induced Hand-Foot Syndrome and Nail Changes: A Review of Clinical Presenta-tion, Etiology, Pathogenesis, and Management. Journal of the American Academy of Dermatology, 71, 787-794. [Google Scholar] [CrossRef] [PubMed]
[14] Urakawa, R., Tarutani, M., Kubota, K., et al. (2019) Hand Foot Syndrome Has the Strongest Impact on QOL in Skin Toxicities of Chemotherapy. Journal of Cancer, 10, 4846-4851. [Google Scholar] [CrossRef] [PubMed]
[15] Nikolaou, V., Syrigos, K. and Saif, M.W. (2016) Incidence and Implications of Chemotherapy Related Hand-Foot Syndrome. Expert Opinion on Drug Safety, 15, 1625-1633. [Google Scholar] [CrossRef] [PubMed]
[16] 吴美玉, 阮靖华, 钟伯雄. 人表皮生长因子的研究进展[J]. 生物工程学报, 2020, 36(12): 2813-2823.
[17] Li, J. and Yan, H. (2018) Skin Toxicity with Anti-EGFR Mono-clonal Antibody in Cancer Patients: A Meta-Analysis of 65 Randomized Controlled Trials. Cancer Chemotherapy and Pharmacology, 82, 571-583. [Google Scholar] [CrossRef] [PubMed]
[18] Zhao, B., Li, J., Chen, Q., et al. (2020) A Treatment Combination of IGF and EGF Promotes Hair Growth in the Angora Rabbit. Genes (Basel), 12, 24. [Google Scholar] [CrossRef] [PubMed]
[19] Purdom, S. and Chen, Q.M. (2005) Epidermal Growth Factor Recep-tor-Dependent and -Independent Pathways in Hydrogen Peroxide-Induced Mitogen-Activated Protein Kinase Activation in Cardiomyocytes and Heart Fibroblasts. Journal of Pharmacology and Experimental Therapeutics, 312, 1179-1186. [Google Scholar] [CrossRef] [PubMed]
[20] 赵宏, 刘昱辉. 人表皮细胞生长因子及其研究进展[J]. 生物技术进展, 2011, 1(2): 122-129.
[21] 郭顺华, 郝晓宇, 庄太凤. 表皮生长因子联合紫草油对新生儿严重臀红的治疗与护理效果[J]. 中国优生与遗传杂志, 2021, 29(1): 131-134.
[22] 赵诚, 单苏圆, 王未娟. 基于转化生长因子β1和血管内皮生长因子研究紫草油促进肛裂术后创面修复的作用及其机制[J]. 中华实验外科杂志, 2021, 38(6): 1137-1140.
[23] 郭琴, 吉津, 刘聪, 等. 复方紫草油促进CO2点阵激光术后创面修复的临床观察[J]. 中国中西医结合皮肤性病学杂志, 2021, 20(5): 487-489.
[24] 张历元, 李元文, 迟庆, 等. 复方紫草油体外抑菌实验研究[J]. 世界中医药, 2019, 14(5): 1133-1138.
[25] 陈丽丽, 杨晓玲, 张艳花, 等. 紫草油涂擦肛周治疗肛周疾病术后的临床观察[J]. 中外医学研究, 2021, 19(17): 53-55.

为你推荐